Lia A Bernardi1, Ronald N Cohen, Mary D Stephenson. 1. University of Chicago Recurrent Pregnancy Loss Program, Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois; Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois.
Abstract
OBJECTIVE: To assess the impact of subclinical hypothyroidism (SCH) in women with recurrent early pregnancy loss (REPL). DESIGN: Observational cohort study. SETTING: REPL program in an academic medical center. PATIENT(S): 286 women with a history of ≥2 pregnancy losses <10 weeks. INTERVENTION(S): From 2004-2007, no treatment for women with SCH (thyroid-stimulating hormone [TSH] >2.5 mIU/L with a normal free thyroxine or free thyroxine index); from 2008 onward, levothyroxine treatment prepregnancy to maintain TSH ≤2.5 mIU/L. MAIN OUTCOME MEASURE(S): Live-birth rate (LBR). RESULT(S): The prevalence of SCH was 55 (19%) of 286 in this REPL cohort. The cumulative LBR was 27 (69%) of 39 for women with SCH versus 104 (74%) of 141 for euthyroid women. The per-pregnancy LBR was 34 (49%) of 69 for SCH versus 129 (58%) of 221 for euthyroid women. When the LBR was compared between treated and untreated SCH, the cumulative LBR was 17 (71%) of 24 versus 10 (67%) of 15, respectively. The per-pregnancy LBR for SCH treated versus untreated women was 22 (48%) of 46 versus 12 (52%) of 23, respectively. CONCLUSION(S): Although there was a high prevalence of SCH in the REPL cohort, there was no statistically significant difference in the subsequent live-birth rate when comparing women with SCH and euthyroid women, or treated and untreated SCH.
OBJECTIVE: To assess the impact of subclinical hypothyroidism (SCH) in women with recurrent early pregnancy loss (REPL). DESIGN: Observational cohort study. SETTING: REPL program in an academic medical center. PATIENT(S): 286 women with a history of ≥2 pregnancy losses <10 weeks. INTERVENTION(S): From 2004-2007, no treatment for women with SCH (thyroid-stimulating hormone [TSH] >2.5 mIU/L with a normal free thyroxine or free thyroxine index); from 2008 onward, levothyroxine treatment prepregnancy to maintain TSH ≤2.5 mIU/L. MAIN OUTCOME MEASURE(S): Live-birth rate (LBR). RESULT(S): The prevalence of SCH was 55 (19%) of 286 in this REPL cohort. The cumulative LBR was 27 (69%) of 39 for women with SCH versus 104 (74%) of 141 for euthyroid women. The per-pregnancy LBR was 34 (49%) of 69 for SCH versus 129 (58%) of 221 for euthyroid women. When the LBR was compared between treated and untreated SCH, the cumulative LBR was 17 (71%) of 24 versus 10 (67%) of 15, respectively. The per-pregnancy LBR for SCH treated versus untreated women was 22 (48%) of 46 versus 12 (52%) of 23, respectively. CONCLUSION(S): Although there was a high prevalence of SCH in the REPL cohort, there was no statistically significant difference in the subsequent live-birth rate when comparing women with SCH and euthyroid women, or treated and untreated SCH.
Authors: B Toth; W Würfel; M K Bohlmann; G Gillessen-Kaesbach; F Nawroth; N Rogenhofer; C Tempfer; T Wischmann; M von Wolff Journal: Geburtshilfe Frauenheilkd Date: 2015-11 Impact factor: 2.915
Authors: Maria C Magnus; Nils-Halvdan Morken; Knut-Arne Wensaas; Allen J Wilcox; Siri E Håberg Journal: PLoS Med Date: 2021-05-10 Impact factor: 11.613
Authors: Hady El Hachem; Vincent Crepaux; Pascale May-Panloup; Philippe Descamps; Guillaume Legendre; Pierre-Emmanuel Bouet Journal: Int J Womens Health Date: 2017-05-17